Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KA2507 |
| Synonyms | |
| Therapy Description |
KA2507 is a selective inhibitor of HDAC6 that regulates cellular response through posttranslational modification of target proteins, potentially leads to anti-tumor activity (PMID: 33947698). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KA2507 | HDAC Inhibitor 45 | KA2507 is a selective inhibitor of HDAC6 that regulates cellular response through posttranslational modification of target proteins, potentially leads to anti-tumor activity (PMID: 33947698). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03008018 | Phase I | KA2507 | Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours | Completed | USA | 0 |